Sign up to save your podcasts
Or
Share An Oral Agent for the Treatment of Diabetic Retinopathy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
An Oral Agent for the Treatment of Diabetic Retinopathy
In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.
View all episodes
By Retina Synthesis
4.5
88 ratings
In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.